Breye Therapeutics ApS - CVR: 40279865

2023, DKK

24.09.2024

Bruttoresultat

-7.812'

Primær drift

-75.372'

Årets resultat

-70.150'

Aktiver

60.682'

Kortfristede aktiver

55.051'

Egenkapital

48.485'

Afkastningsgrad

-124 %

Soliditetsgrad

80 %

Likviditetsgrad

+500%

Resultat

24.09.2024

Årsrapport	2023 24.09.2024	2022 29.09.2023	2021 31.08.2022	2020 14.09.2021	2019 22.07.2020
Nettoomsætning
Bruttoresultat	-7.812.131	-2.882.747	0	0	0
Resultat af primær drift	-75.372.328	-19.836.072	-737.543	-314.819	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0
Finansielle indtægter	817.187	33.937	167.136	0	0
Finansieringsomkostninger	-1.090.613	-900.034	0	0	0
Andre finansielle omkostninger	0	0	-68.304	-27.649	-12.914
Resultat før skat	-75.645.754	-20.776.942	-780.005	-342.468	343.387
Resultat	-70.150.057	-14.574.884	-780.005	-289.668	264.429
Forslag til udbytte	0	0	0	0	0

Aktiver

24.09.2024

Årsrapport	2023 24.09.2024	2022 29.09.2023	2021 31.08.2022	2020 14.09.2021	2019 22.07.2020
Kortfristede varebeholdninger	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	8.551.953	7.389.789	613.841	343.614	459.412
Likvider	46.499.489	11.385.341	2.514.387	8.201.582	14.266
Kortfristede aktiver	55.051.442	18.775.130	3.128.228	8.545.196	473.678
Immaterielle aktiver og goodwill	5.558.697	5.955.747	14.077.206	5.603.001	0
Finansielle anlægsaktiver	54.068	52.750	1.540.457	26.032	0
Materielle aktiver	17.652	31.773	0	0	0
Langfristede aktiver	5.630.417	6.040.270	15.617.663	5.629.033	0
Aktiver	60.681.859	24.815.400	18.745.891	14.174.229	473.678

Aktiver

24.09.2024

Passiver

24.09.2024

Årsrapport	2023 24.09.2024	2022 29.09.2023	2021 31.08.2022	2020 14.09.2021	2019 22.07.2020
Forslag til udbytte	0	0	0	0	0
Egenkapital	48.485.471	14.526.382	-751.744	28.261	314.429
Hensatte forpligtelser	0	0	0	0	52.800
Langfristet gæld til banker	0	0	7.277.673	6.943.511	0
Anden langfristet gæld		0	0	0	0
Leverandører af varer og tjenesteydelser	4.766.554	2.526.485	909.679	224.449	20.000
Kortfristede forpligtelser	8.429.581	3.188.119	1.019.651	331.627	106.449
Gældsforpligtelser	12.196.388	10.289.018	19.497.635	14.145.968	106.449
Forpligtelser	12.196.388	10.289.018	19.497.635	14.145.968	106.449
Passiver	60.681.859	24.815.400	18.745.891	14.174.229	473.678

Passiver

24.09.2024

Nøgletal

24.09.2024

Årsrapport	2023 24.09.2024	2022 29.09.2023	2021 31.08.2022	2020 14.09.2021	2019 22.07.2020
Afkastningsgrad	-124,2 %	-79,9 %	-3,9 %	-2,2 %	Na.
Dækningsgrad	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-144,7 %	-100,3 %	103,8 %	-1.025,0 %	84,1 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-6.911,0 %	-2.203,9 %	Na.	Na.	Na.
Soliditestgrad	79,9 %	58,5 %	-4,0 %	0,2 %	66,4 %
Likviditetsgrad	653,1 %	588,9 %	306,8 %	2.576,7 %	445,0 %

Resultat

24.09.2024

Gæld

24.09.2024

Årsrapport

24.09.2024

Nyeste:01.04.2023- 31.03.2024(offentliggjort: 24.09.2024)

Information om virksomhedens regnskabsklasse:The annual report of Breye Therapeutics ApS for 2022/23 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

24.09.2024

Dato for ledelsens godkendelse af årsrapporten:2024-09-17

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of Breye Therapeutics ApS for the financial year 1 April 2023 - 31 March 2024.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The Company, Breye Therapeutics ApS, is a clinical stage biopharmaceutical company developing first-in-class and orally administered therapies suited for early treatment intervention in patients with diabetic retinopathy (DR) and age-related macular degeneration (AMD) being at risk of further disease progression and vision loss. Diabetic retinopathy is the leading cause of blindness among working age adults and AMD is the leading cause of blindness within the elderly population. Globally there are more than 120 million people suffering from DR and 200 million people have AMD. With more than 1 billion people being obese today and 20% of the world’s population being older than 60 years of age, both eye diseases are projected to increase in prevalence over the coming decades. Currently available therapies require needle injections administered directly into the eye, and despite the burden of repeated needle injections, the market for these therapies has grown to USD 15 billion annually. The prospect of developing orally administered therapies could help very large groups of patients in need of better and non-invasive therapies. The ambition is to treat patients at moderate to severe stages of disease and thereby help prevent further disease progression to irreversible eye damage and the need for needle injections administered into the eyes. The company's lead therapy, danegaptide, is a clinical asset with a documented safety profile in human trial subjects and has been in licensed from Zealand Pharma A/S. It is a small molecule suitable for oral therapy which can uniquely address a large and growing unmet medical need for more effective and less burdensome therapies for patients with DR. During the reporting period, the Company has advanced this asset into clinical testing in patients with DR and is preparing for phase 2 clinical testing. A second therapeutic program was aquired from Golgi Neurosciences S. r.l. which is in pre-clinical testing with the target of developing an oral medication for patients with AMD. The Company, Breye Therapeutics ApS, has an experienced management team within drug development and is working with world leading scientists and retinal specialists to advance its early portfolio of products.